Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali
Status:
COMPLETED
Trial end date:
2023-05-05
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting biosimilar insulin glargine delivered by reusable pens combined with short-acting insulin via needle and syringe.
Phase:
PHASE4
Details
Lead Sponsor:
Life for a Child Program, Diabetes Australia
Collaborators:
Centre Hospitalier du Luxembourg Hospital of Mali Sante Diabete Mali University Hospital, Geneva